Latest News about Biotech
Recent news which mentions Biotech
From Benzinga
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target
February 26, 2025
From Benzinga
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
February 26, 2025
From Benzinga
AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With Widely Cancer Medicines
February 26, 2025
From Benzinga
From Benzinga
Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss
February 25, 2025
From Benzinga
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder
February 25, 2025
From Benzinga
From Benzinga
From Benzinga
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
February 24, 2025
From Benzinga
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
February 24, 2025
From Benzinga
Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
February 24, 2025
From Benzinga
From Benzinga
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
February 24, 2025
From Benzinga
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients
February 24, 2025
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free